Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products
Executive Summary
Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23
You may also be interested in...
Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs
Merck Faces Varicella-Zoster Virus Supply Shortage For Vaccine Production
Merck does not expect problems in the production of bulk varicella-zoster virus vaccine to affect near-term supplies of individual products that contain the virus - the varicella vaccine Varivax, the herpes zoster vaccine Zostavax, and the measles, mumps, rubella and varicella (MMR-V) combination ProQuad
Merck’s Licensing Philosophy Mixes Acquisitions And Development Deals
Merck is bolstering its pipeline through acquisitions and licensing deals, many in biotech. The drug maker evaluates 6,000 opportunities per year and signed 44 transactions in 2005, in line with its projections of about 50 deals (1"The Pink Sheet" Jan. 10, 2005, p. 35). Merck VP & Chief Licensing Officer Barbara Yanni recently sat down with "The Pink Sheet" DAILY to outline the company's licensing strategy and talk about plans for future growth.